ELI LILLY AND COMPANY Interest Expense Nonoperating
ELI LILLY AND COMPANY (LLY) reported Interest Expense Nonoperating of $895.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-02-12
- ELI LILLY AND COMPANY interest expense nonoperating for the quarter ending 2025-12-31 was $222.60M, a 1.11% decline year-over-year.
- ELI LILLY AND COMPANY interest expense nonoperating for the quarter ending 2025-09-30 was $179.60M, a 6.80% decline year-over-year.
- ELI LILLY AND COMPANY interest expense nonoperating for the quarter ending 2025-06-30 was $249.00M, a 35.62% increase year-over-year.
- ELI LILLY AND COMPANY interest expense nonoperating for the quarter ending 2025-03-31 was $243.70M, a 35.69% increase year-over-year.
- ELI LILLY AND COMPANY interest expense nonoperating for fiscal 2025 was $895.00M, a 14.60% increase from fiscal 2024.
- ELI LILLY AND COMPANY interest expense nonoperating for fiscal 2024 was $781.00M, a 60.70% increase from fiscal 2023.
- ELI LILLY AND COMPANY interest expense nonoperating for fiscal 2023 was $486.00M, a 46.56% increase from fiscal 2022.
- ELI LILLY AND COMPANY interest expense nonoperating for fiscal 2022 was $331.60M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month | Interest Expense Nonoperating 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $222.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $402.20M derived: sum of 2 quarters · filed 2026-02-12 | $651.20M derived: sum of 3 quarters · filed 2026-02-12 | $895.00M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $179.60M 10-Q · filed 2025-10-30 | $428.60M derived: sum of 2 quarters · filed 2025-10-30 | $672.40M 10-Q · filed 2025-10-30 | $897.40M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-06-30 | $249.00M 10-Q · filed 2025-08-07 | $492.70M 10-Q · filed 2025-08-07 | $717.80M derived: sum of 3 quarters · filed 2026-02-12 | $910.50M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-03-31 | $243.70M 10-Q · filed 2025-05-01 | $468.80M derived: sum of 2 quarters · filed 2026-02-12 | $661.50M derived: sum of 3 quarters · filed 2026-02-12 | $845.10M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | $225.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $417.80M derived: sum of 2 quarters · filed 2026-02-12 | $601.40M derived: sum of 3 quarters · filed 2026-02-12 | $781.00M 10-K · filed 2026-02-12 | $780.60M 10-K · filed 2025-02-19 |
| 2024-09-30 | $192.70M 10-Q · filed 2025-10-30 | $376.30M derived: sum of 2 quarters · filed 2025-10-30 | $555.90M 10-Q · filed 2025-10-30 | $694.20M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-06-30 | $183.60M 10-Q · filed 2025-08-07 | $363.20M 10-Q · filed 2025-08-07 | $501.50M derived: sum of 3 quarters · filed 2026-02-12 | $626.10M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-03-31 | $179.60M 10-Q · filed 2025-05-01 | $317.90M derived: sum of 2 quarters · filed 2026-02-12 | $442.50M derived: sum of 3 quarters · filed 2026-02-12 | $562.80M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2023-12-31 | $138.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $262.90M derived: sum of 2 quarters · filed 2026-02-12 | $383.20M derived: sum of 3 quarters · filed 2026-02-12 | $486.00M 10-K · filed 2026-02-12 | $485.90M 10-K · filed 2025-02-19 |
| 2023-09-30 | $124.60M 10-Q · filed 2024-10-30 | $244.90M derived: sum of 2 quarters · filed 2024-10-30 | $347.70M 10-Q · filed 2024-10-30 | ||
| 2023-06-30 | $120.30M 10-Q · filed 2024-08-08 | $223.10M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $331.60M 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |